Mutations in TRIM63 cause an autosomal-recessive form of hypertrophic cardiomyopathy.
Joel Salazar-Mendiguchía,Juan Pablo Ochoa,Julián Palomino-Doza,Fernando Domínguez,Carles Díez-López,Mohammed Shakil Akhtar,Soraya Ramiro-León,María M Clemente,Antonia Pérez-Cejas,María Robledo,Iria Gomez-Diaz,María Luisa Peña-Peña,Vicente Climent,Francisco Salmerón-Martínez,Celestino Hernández,Pablo Elpidio García-Granja,M Victoria Mogollón,Ivonne J. Cárdenas-Reyes,Marcos Cicerchia,Diego García-Giustiniani,Arsonval Lamounier,Belén Gil-Fournier,Felicitas Diaz-Flores,Rafael Salguero,Luis Santomé,Petros Syrris,Montse Olivé,Pablo García-Pavía,Martin Ortiz-Genga,Perry M. Elliott,Lorenzo Monserrat +30 more
TLDR
TRIM63 appears to be an uncommon cause of HCM inherited in an autosomal-recessive manner and associated with concentric LVH and a high rate of LV dysfunction.Abstract:
Objective Up to 50% of patients with hypertrophic cardiomyopathy (HCM) show no disease-causing variants in genetic studies. TRIM63 has been suggested as a candidate gene for the development of cardiomyopathies, although evidence for a causative role in HCM is limited. We sought to investigate the relationship between rare variants in TRIM63 and the development of HCM. Methods TRIM63 was sequenced by next generation sequencing in 4867 index cases with a clinical diagnosis of HCM and in 3628 probands with other cardiomyopathies. Additionally, 3136 index cases with familial cardiovascular diseases other than cardiomyopathy (mainly channelopathies and aortic diseases) were used as controls. Results Sixteen index cases with rare homozygous or compound heterozygous variants in TRIM63 (15 HCM and one restrictive cardiomyopathy) were included. No homozygous or compound heterozygous were identified in the control population. Familial evaluation showed that only homozygous and compound heterozygous had signs of disease, whereas all heterozygous family members were healthy. The mean age at diagnosis was 35 years (range 15–69). Fifty per cent of patients had concentric left ventricular hypertrophy (LVH) and 45% were asymptomatic at the moment of the first examination. Significant degrees of late gadolinium enhancement were detected in 80% of affected individuals, and 20% of patients had left ventricular (LV) systolic dysfunction. Fifty per cent had non-sustained ventricular tachycardia. Twenty per cent of patients suffered an adverse cerebrovascular event (20%). Conclusion TRIM63 appears to be an uncommon cause of HCM inherited in an autosomal-recessive manner and associated with concentric LVH and a high rate of LV dysfunction.read more
Citations
More filters
Journal ArticleDOI
Target and tissue selectivity of PROTAC degraders.
TL;DR: Critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity are provided.
Journal ArticleDOI
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies
TL;DR: Walsh et al. as discussed by the authors explored the complex contribution of genes encoding non-sarcomeric proteins that are robustly associated with non-syndromic or isolated hypertrophic cardiomyopathy across the full range of variant classes, from common regulatory variants to complete gene knockouts.
Journal ArticleDOI
Molecular Genetic Basis of Hypertrophic Cardiomyopathy.
TL;DR: The most common causal genes for HCM are β-myosin heavy chain and myosin binding protein C (myH7 and MYBPC3).
Journal ArticleDOI
Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics.
Eloisa Arbustini,Elijah R. Behr,Lucie Carrier,Cornelia C. van Duijn,Paul C. Evans,Valentina Favalli,P. Van der Harst,Kristina H. Haugaa,Guillaume Jondeau,Stefan Kääb,Juan Pablo Kaski,Maryam Kavousi,Bart Loeys,Antonis Pantazis,Yigal M. Pinto,Heribert Schunkert,Alessandro Di Toro,Thomas Thum,Mario Urtis,Johannes Waltenberger,Perry M. Elliott +20 more
TL;DR: The contribution of clinical criteria to the interpretation of genetic variants using heritable Mendelian cardiomyopathies as an example is described and a partnership between clinicians and patients helps to solve major uncertainties and provides reliable and clinically actionable information.
Journal ArticleDOI
Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules.
TL;DR: The present study could deepen the understanding of the molecular mechanism of obesityassociated type 2 diabetes mellitus, which could be useful in developing clinical treatments of obesity associated type 2abetes mellitus.
References
More filters
Journal ArticleDOI
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards,Nazneen Aziz,Nazneen Aziz,Sherri J. Bale,David P. Bick,Soma Das,Julie M. Gastier-Foster,Wayne W. Grody,Madhuri Hegde,Elaine Lyon,Elaine B. Spector,Karl V. Voelkerding,Heidi L. Rehm +12 more
TL;DR: Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends thatclinical molecular genetic testing should be performed in a Clinical Laboratory Improvement Amendments–approved laboratory, with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or the equivalent.
Journal ArticleDOI
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
Perry M. Elliott,Aris Anastasakis,Michael A. Borger,Martin Borggrefe,Franco Cecchi,Philippe Charron,Albert Hagège,Antoine Lafont,Giuseppe Limongelli,Heiko Mahrholdt,William J. McKenna,Jens Mogensen,Petros Nihoyannopoulos,Stefano Nistri,Petronella G. Pieper,Burkert Pieske,Claudio Rapezzi,Frans H. Rutten,Christoph Tillmanns,Hugh Watkins +19 more
TL;DR: The objective of this study was to establish a baseline level of confidence that the once-in-a-lifetime implantation trial—Reduce Inappropriate Therapy protocol can be trusted to provide safe and effective treatment for cardiac arrhythmia and stroke-like episodes.
Journal ArticleDOI
Hypertrophic Cardiomyopathy Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy
Pascale Richard,Philippe Charron,Lucie Carrier,C. Ledeuil,Theary Cheav,Claire Pichereau,A. Benaiche,Richard Isnard,Olivier Dubourg,Marc Burban,Jean Pierre Gueffet,Alain Millaire,Michel Desnos,Ketty Schwartz,Bernard Hainque,Michel Komajda +15 more
TL;DR: A systematic screening of 9 genes in a large population to evaluate the distribution of the disease genes, and to determine the best molecular strategy in clinical practice, found that screening of already known mutations is not helpful and several mutations should be searched.
Journal ArticleDOI
TRIM family proteins and their emerging roles in innate immunity
TL;DR: Recent data are described that reveal broader antiviral and antimicrobial activities of TRIM proteins and their involvement in the regulation of pathogen-recognition and transcriptional pathways in host defence is discussed.
Journal ArticleDOI
Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy
Kevin M. Harris,Paolo Spirito,Martin S. Maron,Andrey G. Zenovich,Francesco Formisano,John R. Lesser,Shannon Mackey-Bojack,Warren J. Manning,James E. Udelson,Barry J. Maron +9 more
TL;DR: ES of nonobstructive HCM has an expanded and more diverse clinical expression than previously appreciated, including occurrence in young patients, heterogeneous patterns of remodeling, frequent association with atrial fibrillation, and impaired LV contractility that precedes cavity dilatation, wall thinning, and heart failure symptoms.
Related Papers (5)
Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy
Robert Roberts,Ulrich Sigwart +1 more